Int Neurourol J.
2011 Jun;15(2):61-63.
Potential Targeting of Siglecs, Mast Cell Inhibitory Receptors, in Interstitial Cystitis
- Affiliations
-
- 1Department of Pharmacology, Inha University School of Medicine, Incheon, Korea. parkshin@inha.ac.kr
- 2Medicinal Toxicology Research Center, Inha Institute of Research for Medical Sciences, and Center for Advanced Medical Education, Inha University College of Medicine by BK-21 Project, Inha University School of Medicine, Incheon, Korea.
- 3Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract
- Mast cell increases and activation are detected in the chronic inflammatory bladder disease interstitial cystitis (IC), and their proinflammatory mediators are felt to contribute to regional pelvic pain and inflammatory pathophysiology. The immunoreceptor tyrosine-based inhibition motif-containing sialic acid-binding immunoglobulin-like lectins (Siglecs) expressed in mast cells could be evaluated as in vivo signaling regulators capable of inhibiting IC-related mast cell activation.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Interleukin-33 as a Potential Therapeutic Target for Interstitial Cystitis: New Perspectives on Mast Cell Regulation
- Interleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's Perspective
- New Insights into the Mechanism of the Down-Regulation of Mast Cells in the Treatment of Interstitial Cystitis: Possible Role of Siglecs
- The Diagnostic Value of Mast Cell Count in Interstitial Cystitis
- Functions of Siglecs in Allergic Inflammation
